The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin’s and non-Hodgkin’s lymphoma survivors


Published in:
Annals of Hematology

Document version:
Publisher's PDF, also known as Version of record

DOI:
10.1007/s00277-011-1274-4

Publication date:
2011

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright, please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 27. Dec. 2020
The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin’s and non-Hodgkin’s lymphoma survivors: a systematic review

Simone Oerlemans · Floortje Mols · Marten R. Nijziel · Marnix Lybeert · Lonneke V. van de Poll-Franse

Abstract Cancer survivors are at risk of experiencing adverse physical and psychosocial effects of their cancer and its treatment. Both Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL) survivors face problems that can affect their health-related quality of life (HRQoL). The authors systematically reviewed the literature on HRQoL among HL and NHL survivors. A PubMed and PsychINFO literature search for original articles published until May 2011 was performed. Twenty-four articles, which met the predefined inclusion criteria, were subjected to a quality checklist. HL survivors showed the most problems in (role) physical, social and cognitive functioning, general health, fatigue and financial problems. In addition, HL survivors treated with a combination of therapies, with older age and female sex reported worse HRQoL. NHL survivors showed the most problems in physical functioning, appetite loss, vitality and financial problems. Having had chemotherapy was negatively associated with HRQoL, but no differences in chemotherapy regimens were found. Furthermore, in NHL survivors not meeting public exercise guidelines, HRQoL is low but can be improved with more exercise. More research on the longitudinal comparison between HL and NHL survivors and healthy controls should be performed in order to better understand the long-term (side) effects of treatment on HRQoL and possibilities to alleviate these.

Keywords Quality of life · Hodgkin’s lymphoma · Non-Hodgkin’s lymphoma · Cancer treatment · Cancer survivors

Introduction

Treatment of cancer has improved considerably in the past decades resulting in more (long-term) survivors. A person diagnosed with cancer is defined a survivor from the moment of diagnosis through the balance of his or her life [1]. The number of cancer survivors in the United States (US) has increased steadily and is currently estimated to be 11.1 million [2]. The number of lymphoma survivors has relatively increased even more. On January 1, 2008, there were approximately 167,000 Hodgkin’s lymphoma (HL) survivors and approximately 454,000 non-Hodgkin’s lymphoma (NHL) survivors in the US [2]. In the Nordic European Countries (NEC: Denmark, Faroe Islands, Finland, Iceland, Norway, Sweden), there were approximately 10,500 HL survivors and approximately 31,500 NHL survivors at the end of 2007 [3].

Although there are similarities between these subtypes of lymphoma, the incidence and age of onset are quite different. The annual incidence of HL is one in 35,000 in the US [2] and one in 47,000 in the NEC [3], with approximately 8,500 new
cases in the US [2] and 558 new cases in the NEC [3] annually. Onset occurs most frequently between the ages of 20 and 35 years. Between 35 and 50 years, it occurs less often especially in females, but from the age of 50 onward there is again a rise in incidence with age [2]. The lifetime prevalence of HL is one in 430 [2]. With respect to NHL, the annual incidence is one in 5,000, with approximately 65,000 new cases in the US [2] and 73,000 new cases in the European Union (NEC numbers are unavailable) [4]. The disease occurs predominantly in individuals aged over 45 years and the lifetime prevalence of NHL is one in 50 [2].

Due to chemotherapy, radiotherapy and stem cell transplantation, the survival of these patients has improved dramatically in the seventies and eighties, but has nowadays levelled off. In effect, most trials focus on maintaining the high level of cure, while reducing the long-term effects of treatment. To date, more than 80% of patients diagnosed with HL are expected to live free of disease for 5 years or more after diagnosis [5]. The overall 5-year survival rate for all types of NHL (1999–2005) is 50–60%. The statistics vary depending on the cell type, stage of disease at diagnosis, treatment and age of the patient [5].

As cancer survivors are living longer, they are at risk of experiencing adverse physical and psychosocial long-term effects of the fact that they had cancer or of their treatment [6–9]. The long-term HL and NHL survivors, especially, face specific problems, concerning mainly chronic medical as well as psychosocial complications that can affect their health-related quality of life (HRQoL). Fatigue, depression, marital disruption and problems with infertility are frequently reported concerns by these survivors, not to mention problems with insurances and mortgages [6, 8–11].

Only recently, the focus of published papers has shifted from improvement of survival to HRQoL. In December 2009, a review concerning HRQoL in lymphoma survivors has been published [12]. This review described the HRQoL of both HL and NHL survivors combined, which may delude conclusions as differences in age of onset, treatment and overall survival time between HL and NHL greatly influences HRQoL. In addition, four prospective and two cross-sectional studies, all published between 2004 and 2009, were not included in this review and especially these prospective studies contain important information. Furthermore, and most important, the review did not provide information about the clinical implications of its findings. Many studies base their conclusions on statistical significance, but clinical significance should also be studied for the representation of clinically important differences to patients. Our review will therefore distinguish itself by a separate discussion of both types of lymphoma, a more complete and updated overview of studies, and by providing information about clinical significance of the findings. The aim of this systematic review was (1) to evaluate the quality of the included studies, (2) to identify the HRQoL domains and symptoms that are clinically relevant affected in HL and NHL survivors, (3) to evaluate the relation between treatment and HRQoL and (4) to evaluate potential differences in socio-demographic and clinical characteristics.

Methods

Search strategy

The electronic databases of PubMed and PsychINFO were searched to find all articles up to May 2011 using the terms ‘Hodgkin’s’ and ‘non-Hodgkin's lymphoma’ in combination with survivors, long-term, (health-related) quality of life, and HRQoL. The reference lists of all publications were checked to retrieve additional publications.

Selection criteria

Studies in English on HRQoL in HL and NHL adult survivors were included if they used a multidimensional HRQoL questionnaire. Studies that merely focused on one-dimensional aspects of HRQoL such as fatigue, anxiety or depression were excluded from this review because this is not consistent with the multidimensional concept of HRQoL (i.e. the existential influence of disease on physical, emotional and social functioning). Also, studies that involved a variety of tumours including HL or NHL, focused on adult survivors of childhood cancer, and studies not published in peer-reviewed journals were excluded. Furthermore, the focus of the study had to be either one or more of the following: (1) comparison with a normative population, (2) studying the relation between treatment and HRQoL, (3) studying the relation between socio-demographic or clinical characteristics and HRQoL.

The search resulted in 270 hits. Based on titles and abstracts, 24 articles met our selection criteria and were included in this review (Fig. 1).

Quality assessment

The methodological quality of the selected studies was assessed using a 12-item standardized checklist of predefined criteria which was a modified version of an established criteria list for systematic reviews (Table 1) [13, 14]. Each item of a study, which met our criteria, was assigned one point. If an item that did not meet our criteria was described insufficiently, or not at all, then zero points were assigned. The highest possible score was 12. Studies scoring ≥8 points were considered to be of ‘high quality’. Studies scoring <6 points or 6–8 points were rated respectively as low and moderate quality.
Criteria for clinically important difference

The following criteria were used to determine clinically important differences. For the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), a score greater than or equal to a 10-point difference on subscales reflects a clinical important difference [9, 15–18]. Concerning the RAND Short Form-36 (SF-36), differences of ≥2 points for role physical functioning; ≥3 points for physical functioning, social functioning, bodily pain, general health, vitality, mental health and the component scales; ≥4 points for role emotional functioning are considered clinically meaningful [19, 20]. For the other questionnaires and some subscales, Norman’s ‘rule of thumb’ was used whereby a ≈0.5 SD difference indicates a threshold of discriminating change in HRQoL scores of a chronic illness [21].

Results

Study characteristics

In total, 24 studies were included (14 HL [9, 15, 16, 22–32] and ten NHL [11, 17, 33–40]) all published between February 1994 and November 2010. Only one study was conducted outside the US and Europe [40]. The time since diagnosis ranged between circa 2 months and 44 years. The most frequently used questionnaires of HRQoL were the EORTC QLQ-C30 (ten studies) [41] and the SF-36 (11 studies) [42]. Two studies used the Schedule for the Evaluation of Individual Quality of Life—Direct Weighting (SEIQoL-DW) [43], and three studies used the Functional Assessment of Cancer Therapy-General (FACT-G) [44].

With respect to HL, two studies had a prospective design, and 12 studies had a cross-sectional design. Of the 14 studies, ten cross-sectional studies compared HL survivors and the general population, two prospective and eight cross-sectional studies evaluated the relation with treatment, and two prospective and nine cross-sectional

Table 1 List of criteria for assessing the methodological quality of studies on health-related quality of life among Hodgkin’s and non-Hodgkin’s lymphoma

<table>
<thead>
<tr>
<th>Positive if with respect to</th>
<th>Quality of life assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A validated (Health-Related) Quality of Life Questionnaire is used (e.g. SF36, EORTC-C30)</td>
<td></td>
</tr>
<tr>
<td>Study population</td>
<td></td>
</tr>
<tr>
<td>2. A description of at least two socio-demographic variables is included</td>
<td></td>
</tr>
<tr>
<td>3. A description of at least two clinical variables of the described patient population (e.g. tumour stage at diagnosis) is present</td>
<td></td>
</tr>
<tr>
<td>4. Inclusion and/or exclusion criteria are described</td>
<td></td>
</tr>
<tr>
<td>5. Participation rates for patient groups are described and are more than 60%</td>
<td></td>
</tr>
<tr>
<td>6. Information is given about the degree of selection of sample (information is given about the ratio respondents vs. non-respondents)</td>
<td></td>
</tr>
<tr>
<td>Study design</td>
<td></td>
</tr>
<tr>
<td>7. The study size consists of at least 50 participants (arbitrarily chosen)</td>
<td></td>
</tr>
<tr>
<td>8. The data are prospectively gathered</td>
<td></td>
</tr>
<tr>
<td>9. The process of data collection is described (e.g. interview or self-report)</td>
<td></td>
</tr>
<tr>
<td>Results</td>
<td></td>
</tr>
<tr>
<td>10. The results are compared between two groups or more (e.g. healthy population, groups with different treatment or age) and/or results are compared with at least two time points (e.g., longitudinally vs. post-treatment)</td>
<td></td>
</tr>
<tr>
<td>11. Mean, median, standard deviations or percentages are reported for the most important outcome measures</td>
<td></td>
</tr>
<tr>
<td>12. Statistical proof for the findings is reported</td>
<td></td>
</tr>
</tbody>
</table>
studies reported about potential differences in socio-demographic and clinical characteristics (Table 2). With respect to NHL, four studies had a prospective design and six studies had a cross-sectional design. Of the ten studies, two prospective and three cross-sectional studies compared NHL survivors and the general population, three prospective and two cross-sectional studies evaluated the relation with treatment, and nine studies reported about the potential differences in socio-demographic and clinical characteristics (Table 3).

The evaluation of the methodological quality of the studies by the reviewers (SO, FM, LP) yielded the following results. On items 1, 5, 7, 8, 9, 11 and 12 there was disagreement once, and on items 2, 3 and 10 there was no disagreement. On items 4 and 6 (see Table 1), there was disagreement a couple of times, mostly due to differences in interpretation of the text. These were solved through discussion in a consensus meeting. The methodological quality of all included studies ranged from 8 to 12 points and was thus considered to be of high quality. General shortcomings concerned mainly the lack of information on non-respondents (n=11) and the lack of a prospective design (n=16).

Hodgkin’s lymphoma

HRQoL domains: HL survivors vs. normative samples

Four cross-sectional studies found clinically important lower physical functioning scores for survivors compared to a normative population [9, 26, 30, 32]. No clinically important differences were found in six studies [15, 22, 24, 27, 28, 31].

Five studies found that HL survivors had clinically important lower scores on social functioning compared to normative samples [9, 15, 22, 24, 26]. Three studies found no clinically important differences on social functioning [27, 28, 30].

One study among 98 survivors that survived more than 8 years found that HL survivors had clinically important lower scores on emotional functioning compared to the normative sample [22] while seven studies found no clinically important differences [9, 15, 24, 26–28, 30].

Five studies found that HL survivors had clinically important lower scores on role physical functioning compared to the normative sample [9, 22, 26, 27, 30]. Three studies found no clinically important differences [15, 24, 28].

No clinically important differences were found between HL survivors and normative samples with respect to Global health state (six studies) [15, 22, 24, 27, 28, 31].

Three cross-sectional studies found that HL survivors had clinically important lower scores on general health compared to the normative sample [9, 26, 30]. Two cross-sectional studies found no clinically important differences on general health [28, 31].

No clinically important differences were found between HL survivors and normative samples regarding mental health scores (four studies) [9, 26, 28, 30].

Symptoms: HL survivors vs. normative samples

Clinically important worse scores of HL survivors were reported on several symptoms; cognitive problems [15, 22, 27], financial difficulties [15, 22, 24], fatigue/vitality [9, 15, 22], dyspnea [22, 27] and insomnia [15, 22] were reported most often. Diarrhoea [22] and pain [26] were reported by one study each. Three studies found no clinically important differences between HL survivors and normative samples [9, 13, 30].

Treatment and HRQoL in HL survivors

One prospective study among 247 early stage HL survivors [23] found clinically important lower scores on vitality among patients treated with a combination of radiotherapy and chemotherapy compared to patients treated with radiotherapy alone, but only in the first year after treatment. This effect was also found in a cross-sectional study among 126 HL survivors in Austria [25]. They reported that patients treated with a combination of radiotherapy and chemotherapy showed clinically important lower scores on physical functioning and clinically important higher scores on pain, fatigue and dyspnea compared to patients who were treated with radiotherapy or chemotherapy alone. Two small cross-sectional studies also found clinical important higher scores on dyspnea. One found that 26 patients treated with mantle field irradiation reported higher scores compared with patients treated without (n=16) [29]. The other study found that 37 patients treated with high dose chemotherapy and stem cell transplantation reported higher scores compared with patients treated with conventional chemotherapy (n=61) [22]. Another prospective and four cross-sectional studies found no effect of treatment on HRQoL [9, 16, 24, 28, 32].

Socio-demographic and clinical characteristics in HL survivors

Three cross-sectional and one prospective study observed that older patients reported clinically important worse outcomes [9, 16, 24, 27]. Six studies reported contradicting differences in HRQoL according to gender [9, 15, 16, 24, 27, 29], three studies found clinically important worse scores for women [9, 24, 27], one found only statistically worse scores for women [16], one found worse scores for men [29] and one found no differences [15].
<table>
<thead>
<tr>
<th>Study, year, country</th>
<th>Number</th>
<th>Mean age, SD or range</th>
<th>Treatment</th>
<th>Time since diagnosis</th>
<th>Design</th>
<th>Quality of life instruments</th>
<th>Comparison norm population</th>
<th>Evaluation treatment effect</th>
<th>Evaluation other characteristics</th>
<th>General conclusions</th>
<th>Methodological quality score (maximum score = 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandt et al., 2010, Germany [22]</td>
<td>98</td>
<td>Mean: not reported; range: 21–72</td>
<td>Conventional chemotherapy vs high-dose chemotherapy and stem cell transplantation</td>
<td>1–24 years</td>
<td>Cross-sectional</td>
<td>EORTC QLQ-C30</td>
<td>Yes, comparison with health population</td>
<td>Yes</td>
<td>No</td>
<td>HL survivors have a reduced HRQoL compared to the healthy population. HL survivors who were treated with conventional chemotherapy had clinically important less dyspnea complaints compared to survivors treated with highdose chemotherapy.</td>
<td>10</td>
</tr>
<tr>
<td>Loge et al., 1999, Norway [9]</td>
<td>459</td>
<td>Mean, 44; SD, 11.8</td>
<td>Chemotherapy, radiotherapy or combined therapy</td>
<td>Mean=12.2 years (3–23)</td>
<td>Cross-sectional</td>
<td>SF-36</td>
<td>Yes, comparison with general population norms</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Ganz et al., 2003, USA [23]</td>
<td>247</td>
<td>Mean, 33; range, 17–85</td>
<td>Radiotherapy vs chemotherapy followed by radiotherapy</td>
<td>Mean=6 months, 1 year, 2 years</td>
<td>Prospective</td>
<td>SF-36</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Patients with early stage HL experience a short-term (6 months) decrease in HRQoL and an increase in symptoms and fatigue with treatment. However, after 1 year these scores returned to baseline scores.</td>
<td>10</td>
</tr>
<tr>
<td>Gil-Fernandez et al., 2003, Spain [24]</td>
<td>46</td>
<td>Mean, 43; range, 55–80</td>
<td>Chemotherapy, radiotherapy or combined therapy</td>
<td>Mean=7.6 years (0.8–22.1)</td>
<td>Cross-sectional</td>
<td>EORTC QLQ-C30</td>
<td>Yes, compared to healthy individuals of the faculty of medicine</td>
<td>Yes</td>
<td>Yes</td>
<td>Statistically significant differences were observed between HL survivors and controls in two functional scales. Physical function was significantly lower in patients than in controls, and the social operation scale that refers to the social familial relationships of the individuals was also lower in patients than in controls. HL survivors also scored worse on the dyspnea scale and reported more economical difficulties. No difference between treatments was found.</td>
<td>10</td>
</tr>
<tr>
<td>Goodman et al., 2008, USA [15]</td>
<td>60</td>
<td>Mean, 43; range, 24–65</td>
<td>Chemotherapy and autologous stem cell rescue</td>
<td>Mean=12 years (6–18)</td>
<td>Cross-sectional</td>
<td>EORTC QLQ-C30</td>
<td>Yes, comparison with the general population</td>
<td>No</td>
<td>Yes</td>
<td>Global HRQoL of HL survivors was comparable with the general population, but for specific domains, respondents’ scores indicated reduced functioning and worse symptoms: cognitive and social functioning, fatigue, insomnia and financial problems.</td>
<td>8</td>
</tr>
<tr>
<td>Greil et al., 1999, Austria [25]</td>
<td>126</td>
<td>Mean, 37; SD, 36.3; range, 6–89</td>
<td>Chemotherapy, radiotherapy or combined therapy</td>
<td>Mean=10.5 years (0.9–34)</td>
<td>Cross-sectional</td>
<td>EORTC QLQ-C30</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>The scores indicate high scores on HRQoL parameters in all subscales in HL survivors after a mean period of 9.1 years from the time of the initial diagnosis. HL survivors treated with combined modality therapy showed worse physical functioning and more fatigue, pain and dyspnea.</td>
<td>10</td>
</tr>
<tr>
<td>Heutte et al., 2009, France [16]</td>
<td>935</td>
<td>Mean: not reported; range: 15–70</td>
<td>Chemotherapy, radiotherapy or combined therapy</td>
<td>Mean=90 months (52–138)</td>
<td>Prospective, longitudinal</td>
<td>EORTC QLQ-C30</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>HL survivors showed a significant improvement in most HRQoL domains within 18 months of the end of treatment, except for cognitive functioning. By contrast, very few patients showed HRQoL impairment. HL survivor scores are similar to the general population matched for age and sex.</td>
<td>12</td>
</tr>
<tr>
<td>Hjermstad et al., 2005, Norway [26]</td>
<td>475</td>
<td>Mean: 46.5D; 11.6</td>
<td>Chemotherapy,</td>
<td>195 months (53–123)</td>
<td>Cross-sectional</td>
<td>SF-36</td>
<td>Yes, comparison</td>
<td>No</td>
<td>No</td>
<td>Overall, HL survivors reported lower HRQoL compared to controls.</td>
<td>11</td>
</tr>
<tr>
<td>Study, year, country</td>
<td>Mean age, SD or range</td>
<td>Treatment</td>
<td>Time since diagnosis</td>
<td>Design</td>
<td>Quality of life instruments</td>
<td>Comparison norm population</td>
<td>Evaluation treatment effect</td>
<td>Evaluation other characteristics</td>
<td>General conclusions</td>
<td>Methodological quality score (maximum score=12)</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>-----------------------</td>
<td>-----------</td>
<td>----------------------</td>
<td>--------</td>
<td>-----------------------------</td>
<td>--------------------------</td>
<td>--------------------------</td>
<td>-----------------------------</td>
<td>------------------------</td>
<td>-----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>2006, Norway [26]</td>
<td>Range: 21–74</td>
<td>Radiotherapy or combined therapy</td>
<td>431)</td>
<td></td>
<td>with nationally representative general practitioner data</td>
<td></td>
<td></td>
<td></td>
<td>HRQoL than the general population. Survivors scored significantly worse on bodily pain, general health, (role) physical functioning and social functioning.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joly et al., 1996, France [27]</td>
<td>Mean, 42; range, 23–85</td>
<td>Chemotherapy, radiotherapy or combined therapy</td>
<td>Mean=10 years (range, 4–17)</td>
<td>Cross-sectional</td>
<td>EORTC QLQ-C30</td>
<td>Yes, case control</td>
<td>No</td>
<td>Yes</td>
<td>Compared to controls, HL patients reported more physical, role and cognitive functioning impairments, as well as dyspnoea and chronic fatigue, while no statistical difference was found in global health status. HRQoL among HL survivors is lower compared to an age-matched normative sample. Survivors scored worse on general health, vitality, social functioning. No differences between treatments were reported.</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Mols et al., 2006, The Netherlands [28]</td>
<td>Not reported</td>
<td>Chemotherapy, radiotherapy or combined therapy</td>
<td>Mean=5–15 years</td>
<td>Population-based, cross-sectional</td>
<td>SF-36</td>
<td>Yes, comparison with an aged matched normative sample</td>
<td>Yes</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norum et al., 1996, Norway [29]</td>
<td>Not reported</td>
<td>Chemotherapy, radiotherapy or combined therapy</td>
<td>16–20 months</td>
<td>Cross-sectional</td>
<td>EORTC QLQ-C30</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>HRQoL among HL survivors is lower compared to an age-matched normative sample. Survivors scored worse on general health, vitality, social functioning. No differences between treatments were reported.</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Van Tulder et al., 1994, The Netherlands [30]</td>
<td>Mean, 47; SD, 11; range, 25–77</td>
<td>Radiotherapy vs. combined therapy</td>
<td>Mean=14 years (10–18)</td>
<td>Cross-sectional</td>
<td>SF-36</td>
<td>Yes, comparison with hospital visitors matched for age and sex</td>
<td>No</td>
<td>No</td>
<td>Self-reported HRQoL of HL survivors is still affected 10 to 18 years after treatment. In particular, physical and role functioning, sexuality and overall health perceptions appear to be compromised.</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Wettergren et al., 2003, Sweden [31]</td>
<td>Mean, 47; SD, 11.9</td>
<td>Chemotherapy, radiotherapy or combined therapy</td>
<td>Mean=14 years</td>
<td>Cross-sectional</td>
<td>SEIQoL-DW</td>
<td>Yes, comparison with a random sample of Swedish citizens</td>
<td>No</td>
<td>Yes</td>
<td>Neither the current status in the different areas nor the HRQoL index score differed between HL survivors and controls. Thoughts and worries around disease, fatigue and loss of energy and late effects on skin and mucous membrane were the most commonly reported problems following HL.</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Wettergren et al., 2003, Sweden [32]</td>
<td>Mean, 47; range, 23–75</td>
<td>Chemotherapy, radiotherapy or combined therapy</td>
<td>Mean=13 years (6–24)</td>
<td>Cross-sectional</td>
<td>SEIQoL-DW and SF-12</td>
<td>Yes, comparison with a random sample of Swedish citizens</td>
<td>Yes</td>
<td>Yes</td>
<td>The HRQoL of survivors who have survived a median of 14 years with HL is similar to that of controls, except for physical functioning.</td>
<td>11</td>
<td></td>
</tr>
</tbody>
</table>

SEIQoL-DW schedule for the evaluation of individual quality of life-direct weighting
<table>
<thead>
<tr>
<th>Study, year, country</th>
<th>Number</th>
<th>Mean age, SD or range</th>
<th>Treatment</th>
<th>Time since diagnosis</th>
<th>Design</th>
<th>Quality of life instruments</th>
<th>Comparison (norm) population</th>
<th>Evaluation treatment effect</th>
<th>Evaluation other characteristics</th>
<th>General conclusions</th>
<th>Methodological quality score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bellizzi et al., 2009, USA [33]</td>
<td>319</td>
<td>Mean, 60; SD, 14.9</td>
<td>Chemotherapy, chemotherapy+ radiation, transplantation</td>
<td>2–6 years</td>
<td>Cross-sectional</td>
<td>SF-36</td>
<td>Yes, survivors who met public health guidelines to those who were sedentary</td>
<td>No</td>
<td>Yes</td>
<td>NHL survivors who met public health guidelines reported better HRQoL than those who were sedentary</td>
<td>11</td>
</tr>
<tr>
<td>Doorduijn et al., 2005, The Netherlands [34]</td>
<td>132</td>
<td>Mean, 72; range, 65–84</td>
<td>CHOP vs. CHOP+ G-CSF chemotherapy</td>
<td>Up till 18 months</td>
<td>Prospective</td>
<td>EORTCQLQ-C30</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>HRQoL was significantly better for NHL survivors in complete response or partial remission than for NHL survivors with progression to relapse</td>
<td>12</td>
</tr>
<tr>
<td>Jerkeman et al., 2005, Norway [17]</td>
<td>95</td>
<td>Mean, 46; range, 18–67</td>
<td>CHOP vs. MACOP-B chemotherapy</td>
<td>Circa 13 months</td>
<td>Prospective</td>
<td>EORTC QLQ-C30</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Before treatment, NHL survivors exhibited lower scores of global HRQoL, physical, role and social functions and more appetite loss compared to the reference population. Role functioning improved compared to baseline, but remained depressed compared to the reference group more than 8 months after end of treatment.</td>
<td>12</td>
</tr>
<tr>
<td>Merli et al., 2004, Italy [35]</td>
<td>91</td>
<td>Mean, 73; range, 66–85</td>
<td>Mini-CEOP vs. P-VEBEC chemotherapy</td>
<td>Circa 2 months</td>
<td>Prospective</td>
<td>EORTC QLQ-C30</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>NHL survivors who met public health guidelines reported better HRQoL than those who were sedentary</td>
<td>10</td>
</tr>
<tr>
<td>Mols et al., 2007, Netherlands [11]</td>
<td>294</td>
<td>Mean, 55</td>
<td>Chemotherapy, radiotherapy or combined therapy</td>
<td>5–15 years</td>
<td>Cross-sectional</td>
<td>SF-36</td>
<td>Yes, comparison with an age- and sex-adjusted reference population sample</td>
<td>Yes</td>
<td>Yes</td>
<td>The improvement of HRQoL at the end of treatment demonstrated that the symptoms of the disease have a greater negative influence on the NHL survivors’ life than do the side effects of therapy.</td>
<td>11</td>
</tr>
<tr>
<td>Pettengell et al., 2008, UK [36]</td>
<td>222</td>
<td>Mean, 60; SD, 10.3</td>
<td>Of/ off chemotherapy vs. on chemotherapy</td>
<td>Not in article</td>
<td>Cross-sectional</td>
<td>FACT-general, FACT-lymphoma</td>
<td>Yes, comparison between disease stages</td>
<td>Yes</td>
<td>Yes</td>
<td>Patients with relapsed disease had the lowest scores on several HRQoL dimensions. Furthermore, they compared patients on and off chemotherapy, and they found that participants receiving chemotherapy were reporting worse on the overall HRQoL scale.</td>
<td>9</td>
</tr>
<tr>
<td>Reeve et al., 2009, USA [37]</td>
<td>53</td>
<td>Not in article</td>
<td>Surgery, radiation, chemotherapy, bone marrow/stem cell transplantation, biologic therapy</td>
<td>2 years</td>
<td>Prospective</td>
<td>SF-36</td>
<td>Yes, comparison with matched control subjects without cancer</td>
<td>No</td>
<td>No</td>
<td>NHL survivors reported significant declines in physical and mental health compared with the control subjects.</td>
<td>11</td>
</tr>
<tr>
<td>Smith et al., 2009, USA [39]</td>
<td>561</td>
<td>Mean, 63; SD, 13.4</td>
<td>Surgery, radiation, chemotherapy, bone marrow/stem cell transplantation, biologic therapy</td>
<td>2–44 years</td>
<td>Cross-sectional</td>
<td>SF-36, FACT-lymphoma</td>
<td>Yes, comparison with general population-based norms</td>
<td>No</td>
<td>Yes</td>
<td>NHL survivors with active disease demonstrated worse physical and mental health functioning, worse HRQoL, and less positive and more negative impacts of cancer compared with disease-free survivors. No significant differences were observed between STS and LTS.</td>
<td>11</td>
</tr>
<tr>
<td>Smith et al., 2010, USA [38]</td>
<td>652</td>
<td>Mean, 63; SD, 13.5</td>
<td>Surgery, radiation, chemotherapy, bone marrow/stem cell transplantation, biologic therapy</td>
<td>2–44 years</td>
<td>Cross-sectional</td>
<td>SF-36, FACT-lymphoma</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Younger NHL survivors reported better physical but worse mental health.</td>
<td>11</td>
</tr>
</tbody>
</table>
sectional studies reported that more advanced disease stage or recurrences were associated with reduced HRQoL; however, no information about clinically important differences could be obtained [15, 32]. One study found remarkably that patients with stage IB–IIB scored significantly and clinically important lower on physical functioning and physical role limitations compared to patients with stage IA–IIB, IIIA–IVA and IIIB–IVB [9].

The impact of length of survival on HRQoL was reported in a cross-sectional study, showing that patients who had survived 10–15 years after diagnosis reported clinically important higher HRQoL scores than patients who had survived 5–9 years [28].

Non-Hodgkin’s lymphoma

**HRQoL domains: NHL survivors vs. normative samples**

In a prospective study among 95 Norwegians [17], patients showed clinically important lower scores on physical functioning up until 5 months after start of therapy compared to the normative sample. However, 8 months after end of treatment, the difference was no longer clinically relevant. A Dutch cross-sectional study among 294 survivors [11] and an American cross-sectional study of 319 survivors found no clinically important lower scores for survivors compared to the normative sample on physical functioning [33]. A cross-sectional study of 761 survivors [39] showed clinically important lower scores on the physical component scale. Another prospective study found statistically lower scores 2 years post-diagnosis; however, no information about clinically important differences could be obtained [37].

A prospective study [17] exhibited clinically important lower scores on social functioning up until 6 months after start of therapy compared to the reference population. However, 8 months after end of treatment, the difference was no longer clinically relevant. Two years post-diagnosis, another prospective study found statistically lower scores; however, no information about clinically important differences could be obtained [37]. A cross-sectional study found no clinically important differences with respect to social functioning [11].

A prospective study [17] showed clinically important lower scores on role physical function compared to the general population, and these scores remained clinically important lower until the end of the study (8 months). Another prospective study found statistically lower scores 2 years post-diagnosis; however, no information about clinically important differences could be obtained [37]. However, a cross-sectional study found no clinically important differences regarding role physical function [11].
Two prospective and a cross-sectional study did not find statistically or clinically important differences with respect to emotional functioning between NHL survivors and the normative populations [11, 17, 37].

A prospective study [17] exhibited clinically important lower scores on global health state up until 5 months after start of therapy compared to the reference population. However, 8 months after the end of treatment, the difference was no longer clinically relevant.

In addition, a cross-sectional study among 294 survivors showed clinically important lower scores on general health [11]. A prospective study found statistically lower scores 2 years post-diagnosis; however, no information about clinically important differences could be obtained [37]. Three cross-sectional studies did not find clinically important differences between NHL survivors and the reference population on mental health [11, 33, 39].

Symptoms: NHL survivors vs. normative samples

A prospective study [17] showed clinically important lower scores on appetite loss, constipation, fatigue and dyspnoea up until respectively 3 months for the first two symptoms and 5 months for the last two symptoms after start of therapy compared to the reference population. However, 8 months after the end of treatment the difference was no longer clinically relevant. Furthermore, they found that 9 months after the end of treatment until the end of the study, survivors had clinically more financial difficulties than the normative sample. A cross-sectional and prospective study found statistically lower scores for survivors on vitality [28, 37], clinically important differences were only found by the cross-sectional study [28].

Treatment and HRQoL in NHL survivors

Three prospective studies showed no significantly different outcomes regarding HRQoL between patients treated with different chemotherapy regimens [17, 34, 35]. Two cross-sectional studies found that, compared to patients who did not receive chemotherapy, patients who did receive chemotherapy experienced clinically important worse overall health functioning [36] and social well-being [11].

Socio-demographic and clinical characteristics in NHL survivors

A prospective study did not find a relation between age and HRQoL outcome [17]. One cross-sectional study [11] found that older patients scored significantly lower on physical functioning than younger patients; however, no information about clinically important differences could be obtained. Another cross-sectional study found clinical meaningful worse physical HRQoL scores for survivors who were older at study enrolment [38].

Two prospective studies [34, 35] found that survivors with progressive disease had clinically meaningful lower HRQoL than patients who were free of disease. Another prospective study found no relation between disease stage and HRQoL [17]. Two cross-sectional studies found statistically lower HRQoL scores for survivors with active (relapsed) disease compared to disease-free survivors [36, 39]; clinically important differences were found in one of them [36].

The impact of length of survival was reported in a cross-sectional study [11] showing that patients who had survived 10–15 years after diagnosis reported clinically important higher HRQoL scores than patients who had survived 5–9 years, but this was not observed by another study [39] that compared short-term (2–5 years after diagnosis) and long-term (≥5 years after diagnosis) survivors.

Two prospective studies [34, 35] investigated HRQoL in elderly patients in relation to the age-adjusted International Prognostic Index which comprises three factors (performance status, lactate dehydrogenase and stage) [45]. These studies found that patients with a low age-adjusted International Prognostic Index had a clinically meaningful better HRQoL than patients with a high age-adjusted International Prognostic Index. One prospective study found no relation between International Prognostic Index and HRQoL [17].

Two cross-sectional studies found that survivors meeting public health exercise guidelines reported a clinically meaningfully better mental and physical health [33, 40] than survivors not meeting these guidelines. Even more important, one of these studies [33] found that there was a significant dose–response pattern in which more exercise resulted in better mental and physical health.

Discussion

This systematic review summarized and evaluated the results of studies focusing on the HRQoL of HL and NHL survivors. It is a remarkable fact that the majority of these studies concerned HL and not NHL, certainly in view of the number of patients being treated (8,500 vs. 65,000) or the number of survivors (165,000 vs. 440,000) [5]. Another point is that the first included study on HRQoL in HL was published in 1994, whereas all included studies on HRQoL in NHL were published after 2004.

The quality scores of the included HL studies ranged from eight to 12 points, which indicate a high methodological quality. The shortcomings of these studies were mainly the lack of a prospective design and lack of information on non-respondents. The HRQoL domains that
were affected the most in these patients and represent clinically important differences to patients were (role) physical, social and cognitive functioning, general health, fatigue and financial problems, and fewer dyspnoea and insomnia. Clinically important differences in emotional functioning, diarrhoea and pain were reported once. No clinically important differences were found in the included studies for physical functioning and mental health. Based on the studies included in this review, HL survivors who received a combination of chemotherapy and radiotherapy [23, 25] had worse scores on HRQoL domains. A clinically important higher score on dyspnoea was found by all therapies, and this suggests that treatment in general results in problems [29]. However, most of the studies found no differences. In addition, HL survivors with older age and females reported worse outcomes. As expected, patients with a longer survival time reported better outcomes compared to those more recently diagnosed.

With respect to the included NHL studies, it was not possible to divide the results section in aggressive and indolent lymphomas due to lack of information within most available studies. The quality scores of NHL studies ranged from nine to 12 points, which indicate a high methodology quality. The shortcomings were mainly a lack of a prospective design. The HRQoL domains that were affected the most in NHL survivors and represent clinically important differences to patients were physical functioning, appetite loss, vitality and financial problems. Clinically important differences in social functioning, role physical functioning and global health were mentioned once up until 5 months after treatment but waned over time. When comparing different chemotherapy regimens, no differences were reported. Nevertheless, having had chemotherapy was associated with clinically important lower scores on social well-being [11] and overall health functioning [36] as reported by two cross-sectional studies in (long-term) cancer survivors. Interestingly, the effect of exercise was reported by two cross-sectional studies in (long-term) cancer survivors. Interestingly, the effect of exercise was studied in NHL patients, whereas this has not been investigated in HL survivors. NHL survivors that met public health exercise guidelines reported a clinically important better HRQoL than survivors that did not meet exercise guidelines [33, 40], and even more important, more exercise resulted in a better mental and physical health [33]. Most studies showed worse HRQoL for survivors with aggressive disease or partial response, no response or progressive disease [34–36, 39], and those with a high age-adjusted Prognostic Index [34, 35], which is well understandable.

The criterion of clinically important differences is very important to specify those domains of HRQoL that are affected in survivors. Most of the included studies based their conclusions only on statistical significance. Sometimes differences between survivors and comparative groups were statistically significant, but not clinically important for patients. Therefore, researchers should always use a criterion for the interpretation of clinical relevance instead of only evaluating the statistical significance to really attribute to the care of patients. Of the 17 included studies that compared HRQoL between survivors and a normative population, only seven [9, 15–17, 28, 32, 39] studies used a criterion to determine clinically relevant differences.

When comparing different studies, certainly in the field of HRQoL, there are many limitations. Seventeen of 22 included papers had a cross-sectional design [9, 11, 15, 24–33, 39, 40]. A limitation of this methodology is that it is not possible to draw causal relationships. In addition, these studies may have survivorship bias because patients that do relatively worse will not participate as they are too ill or dead. A prospective design study provides better relevant answers about causality, for example the temporal direction between treatment and HRQoL, but only five studies had this design. Also, the lack of information in some studies on non-respondents or possible bias makes it more difficult to determine the trustworthiness of a study. Future studies should therefore always try to collect data on non-respondents or discuss the possible risk of bias. Although there are inherent relationships between HRQoL dimensions, we discussed the dimensions separately to identify which specific dimensions are most affected. This does not mean that the unmentioned dimensions could not be affected. However, the underlying mechanisms between the relations in HRQoL dimensions and symptoms are understudied and not yet clear. Therefore, studies focusing on symptom clustering are needed.

The different HRQoL questionnaires used, predominantly the EORTC QLQ-C30 (disease-specific questionnaire) and the SF-36 (generic questionnaire) made it difficult to compare results, as the various scales do not exactly measure the same HRQoL dimensions. The questionnaires in the included studies were almost all generic or disease specific. Generic questionnaires are designed to measure health in general, and are therefore appropriate for a wide range of patient groups and also the general population, but are less sensitive to detect certain aspects of disease and treatment that are relevant to a specific patient group. The EORTC QLQ-C30 is a disease specific questionnaire, but consists of such questions that this questionnaire is also applicable to the general population [46]. In addition to these generic and disease-specific questionnaires, lymphoma-specific questionnaires should be used to detect, with more sensibility, side effects and symptoms particularly relevant to HL and NHL survivors. However, cancer-specific questionnaires are relatively new and underdeveloped and therefore used infrequently. Only two studies [36, 39] used a lymphoma-specific questionnaire, the FACT-lymphoma, which was developed in 2004 [44].

The American Cancer Society defines ‘long-term survivors’ as every person who is still alive 5 years after diagnosis [47]. Six studies, five HL [15, 28, 30–32] and one NHL [11], focused on patients who had survived more than
5 years. Only one recent study focused on the longitudinal HRQoL of HL survivors [16]. Especially these kinds of studies are important in view of the growing number of survivors to identify as soon as possible negative long-term effects, certainly when taken into consideration the implementation of new treatments.

If we compare the results of the 11 cross-sectional and two prospective studies among the HL survivors, some cross-sectional studies are consistent with the prospective studies on points as comparison with the norm population, relation with received treatment, and socio-demographic and clinical differences. However, if we compare the two prospective HL studies, one [23] did find a relation with treatment while the other [16] did not. With respect to NHL studies, again some of the cross-sectional studies (four) are consistent with the prospective ones. However, if we compare the three prospective studies, only consistent results concerning the absence of the relation with treatment on HRQoL were found [17, 34, 35].

In conclusion, the reviewed literature about the HRQoL of HL and NHL survivors reflects that several domains, even in long-term survivors, are affected. Overall, HL survivors experience the most problems in (role) physical, social and cognitive functioning, general health, fatigue and financial problems. In addition, HL survivors with older age and female sex reported worse outcomes. NHL survivors experience the most problems in physical functioning, appetite loss, vitality and financial problems. However, these results are less clear as only a limited number of studies are performed among NHL survivors. Furthermore, importantly the HRQoL in NHL survivors not meeting public exercise guidelines is low, but can be improved with more exercise. More research on the longitudinal comparison between HL and NHL survivors and healthy controls should be performed. Lymphoma-specific questionnaires should be further developed to better understand in detail the side effects of treatment on HL and NHL survivors.

Acknowledgements This study was financially supported by the Jonker-Driessen Foundation and ZonMW—the Netherlands organization for health research and development. There were no financial disclosures.

Conflict of interest There is no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

22. Brandt J, Dietrich S, Meissner J, Neben K, Ho AD, Witzens-Harig
23. Norman GR, Sloan JA, Wyrwich KW (2003) Interpretation of
35. Merli F, Bertini M, Luminari S, Mozzana R, Berte R, Trotzini M,
37. Reeve BB, Potosky AL, Smith AW, Han PK, Hays RD, Davis
38. Smith MK, Crespi CM, Petersen L, Zimmerman S, Ganz PA
41. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A,
42. Browne JP, O’Boyle CA, McGeen HM, McDonald NJ, Joyce CR
43. Browne JP, O’Boyle CA, McGeen HM, McDonald NJ, Joyce CR
44. Browne JP, O’Boyle CA, McGeen HM, McDonald NJ, Joyce CR
45. Browne JP, O’Boyle CA, McGeen HM, McDonald NJ, Joyce CR
46. van de Poll-Franse L V, Mols F, Gundy CM, Creutzberg CL, Nout